Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sevelamer
Drug ID BADD_D02012
Description Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Indications and Usage For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Marketing Status Prescription; Discontinued
ATC Code V03AE02
DrugBank ID DB00658
KEGG ID D08512
MeSH ID D000069603
PubChem ID 3085017
TTD Drug ID D03MZQ
NDC Product Code Not Available
Synonyms Sevelamer | GT335-012 | GT335 012 | GT335012 | Sevelamer Hydrochloride | Hydrochloride, Sevelamer | RenaGel | Sevelamer Carbonate | Carbonate, Sevelamer
Chemical Information
Molecular Formula C6H12ClNO
CAS Registry Number 52757-95-6
SMILES C=CCN.C1C(O1)CCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal inflammation07.08.03.0070.002962%Not Available
Skin haemorrhage24.07.06.009; 23.06.07.0010.001975%Not Available
Gastrointestinal sounds abnormal07.01.01.0020.001975%Not Available
Medication residue present13.15.01.032--Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Pneumonia influenzal22.07.05.008; 11.05.03.0030.000515%Not Available
Crystal deposit intestine13.05.03.0020.032586%Not Available
Gastrointestinal mucosal disorder07.11.03.0080.009874%Not Available
Coma scale abnormal13.07.03.0120.001975%Not Available
The 6th Page    First    Pre   6    Total 6 Pages